Background. In the current era of universal immunization of young children with pneumococcal conjugate vaccine, it is unclear whether the high risk ratios for pneumococcal disease previously attributed to specified chronic conditions have persisted. In addition, further analysis of pneumococcal disease risk may clarify whether certain chronic conditions that currently are not specified as significantly increasing the risk of pneumococcal disease should be so considered.
In the era prior to widespread pneumococcal vaccination, Babl and colleagues reported that children with asplenia, immunosuppression, human immunodeficiency virus (HIV) infection, nephrotic syndrome, and advanced liver disease had incidence rates of invasive pneumococcal disease (IPD) that were up to 100-fold greater than rates among children without these and other risk conditions in the same age group, likely reflecting a lack of effective host defenses [1] . Recent studies [2] [3] [4] have reported that children with malignancy, primary immunodeficiency, or HIV infection, and those receiving immunosuppressive treatment continue to be at high risk for IPD despite high rates of 7-valent pneumococcal conjugate vaccine (PCV7) uptake.
Following licensure of PCV7 in 2000, the Advisory Committee on Immunization Practices (ACIP) recommended universal immunization for all children <24 months of age as well as children with risk factors for pneumococcal disease through age 59 months [5] . With the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) in 2010, the ACIP and the American Academy of Pediatrics (AAP) recommended PCV for immunocompetent children with chronic heart and lung disease, diabetes mellitus, cerebrospinal fluid leaks, and cochlear implants through 71 months of age [6, 7] , as well as for high-risk children with defects in host defenses. Following the licensure of PCV13 for children aged 6-18 years, the ACIP recommended immunization for PCV13-naive children in that age group with anatomic or functional asplenia (including sickle cell disease) and HIV infection [6] . We report a large retrospective cohort analysis to determine whether children with chronic medical conditions not associated with immunodeficiency remained at increased risk for IPD, pneumococcal pneumonia, or all-cause pneumonia. We also sought to better understand the role that asthma may play in increasing the risk for pneumococcal disease in children 5-17 years of age [8, 9] .
METHODS

Study Design
A retrospective cohort design was used. Study cohorts were identified at the beginning of each calendar year for the period 2007-2010, and study subjects were characterized in terms of the presence of underlying medical conditions (ie, risk profile) based on information recorded at any time prior to January 1 of that calendar year. For each cohort, episodes of disease (ie, IPD, pneumococcal pneumonia, and all-cause pneumonia) were ascertained over the 1-year period beginning on January 1 of each corresponding year and ending on December 31 of that year (or the date of loss to follow-up, if earlier). Subjects who met criteria for inclusion in multiple calendar years contributed a corresponding number of observations to analyses.
Data Source
Data for this study were collected from 3 large integrated healthcare claims databases. The 3 databases-(1) Truven Health Analytics MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Databases; (2) IMS LifeLink PharMetrics Health Plan Claims Database; and (3) Optum Research Database-each comprise medical and outpatient pharmacy claims from a large number of private US health plans. A description of the study databases is in the Supplementary Appendix.
Study Population
The study population comprised children <18 years of age who were enrolled in participating health plans on the first day of 1 or more calendar years from 2007 to 2010, and all newborns who were enrolled during this period. Children who were not continuously eligible for comprehensive health (ie, medical and drug) benefits for at least 1 year prior to January 1 of 1 or more study years were excluded from the study population. Newborns in a given year, and those <6 months of age as of January 1 in a given year, were not subject to this exclusionary criterion. Study subjects were characterized by the presence of selected medical conditions (ie, risk profile) based on information recorded at any time prior to January 1 of each calendar year, and stratified by age (<5 and 5-17 years). For newborns, age was determined based on their health plan eligibility start date; for all others, age was determined assuming a birth date of June 30 in their birth year.
Subjects were classified into 3 different risk profile groups (high-risk, at-risk, no at-risk/high-risk conditions) based on the presence/absence of medical conditions that are current indications for pneumococcal vaccination among children and adults, in accordance with recommendations set forth by the ACIP and AAP [7, 9] ; asthma, chronic steroid use, trisomy 21, neuromuscular disorders/seizures, and prematurity/low birth weight (identified based on International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] diagnosis codes 765.0 [extreme immaturity, usually a birth weight <1000 g] and 765.1 [other preterm infants, usually a birth weight 1000-2499 g]) also were considered at-risk conditions. High-risk children included those who had sickle cell disease or other hemoglobninopathies, functional or anatomic asplenia, HIV infection, chronic renal disease and nephrotic syndrome; were immunocompromised; or had a cochlear implant. At-risk children included those who were immunocompetent with 1 or more specified chronic medical conditions. High-risk and at-risk medical conditions were ascertained using ICD-9-CM diagnosis codes, ICD-9-CM/Healthcare Common Procedure Coding System (HCPCS) procedure codes, and HCPCS/National Drug Code (NDC) drug codes recorded any time prior to the beginning of the corresponding study year. Operational algorithms that were used to identify high-risk and at-risk conditions are available in Supplementary Tables 1 and 2. All children who met the minimum qualifying criteria based on any of the evidence (ie, diagnosis, procedure, drug codes) as set forth in the operational algorithms were designated as having the condition of interest.
At-risk children with an asthma diagnosis were further stratified by asthma severity based on evidence of disease-related drug use and/or hospitalization in the 365-day period prior to each study year. Severe asthma was defined as ≥30 days of oral steroids, ≥1 filled prescription for a monoclonal antibody, or ≥1 hospitalization for asthma with length of stay (LOS) ≥2 days. Moderate asthma was defined as ≥90 days of inhaled corticosteroids, ≥90 days of long-acting β-agonists, ≥1 filled prescription for a leukotriene modifier, 1-29 days of oral steroids, or ≥1 hospitalization for asthma with LOS <2 days. Mild asthma was defined as the absence of moderate or severe asthma.
Study Measures
Episodes of IPD, pneumococcal pneumonia, and all-cause pneumonia were ascertained beginning on January 1 and ending on December 31 of each study year (or the date of loss to follow-up, if prior to December 31). Disease episodes were identified using operational algorithms based on ICD-9-CM diagnosis codes and HCPCS/NDC drug codes (Supplementary Table 3 ). Multiple episodes of IPD, pneumococcal pneumonia, and allcause pneumonia, respectively, for a given patient during a given study year were included if they were separated by at least 90 days. Study measures were thus defined as simple count variables, and captured the number of unique episodes of disease in each subgroup (as defined by age and risk profile) during the calendar year.
Statistical Analyses
Crude rates of disease episodes were estimated for subgroups of children <5 years of age and children 5-17 years of age, respectively, defined on the basis of their risk profile (ie, at-risk, highrisk, no at-risk/high-risk conditions). Rates of disease episodes also were estimated for subgroups of children within each age group defined on the basis of individual medical conditions, as well as for at-risk children with asthma by asthma severity and by the total number of at-risk conditions; children with ≥1 at-risk condition, and children with ≥1 high-risk condition, were considered in each of the respective subgroups. Rates were expressed per 100 000 person-years.
Rate ratios comparing crude rates of disease episodes between children with at-risk and high-risk conditions, and those without such conditions, were estimated separately for those <5 years of age and 5-17 years of age. Rate ratios also were estimated for children with individual medical conditions, as well as for at-risk children with asthma by asthma severity and by the total number of at-risk conditions, vs counterparts without any at-risk/high-risk conditions, stratified by age. Distributions of children by other baseline factors (ie, sex, geographic region of residence) were generally similar between risk groups and thus these factors were not considered in analyses. Rate ratios were estimated using a Poisson distribution.
RESULTS
Characteristics of the Study Population
Children <5 years and 5-17 years of age who qualified for inclusion contributed a total of 6.0 million and 20.5 million personyears of observation, respectively. Approximately 92% of children had none of the selected chronic or immunocompromising conditions, and about 7% in each age group had ≥1 at-risk condition (and no high-risk conditions); <1% had a high-risk condition ( person-level results).
Among children <5 years of age with at-risk conditions, prematurity/low birth weight (46%), asthma (36%), chronic heart disease (13%), and chronic lung disease (12%) were common; 13% had >1 at-risk condition, and the most common combinations of at-risk conditions were prematurity/chronic heart disease (23%), chronic lung disease/asthma (14%), and prematurity/asthma (12%). Among children 5-17 years of age with at-risk conditions, asthma (72%) and neuromuscular/seizure disorders (11%) were common; 5% had >1 at-risk condition, and the most common combinations were asthma/ chronic lung disease (41%), asthma/neuromuscular disorders (17%), and asthma/chronic heart disease (7%).
Rates of Disease
Rates of IPD were 11.2 (95% confidence interval [CI], 7.0-17.9) and 40.1 (95% CI, 28.8-56.0) times higher among high-risk children <5 years and 5-17 years of age, respectively, vs agestratified counterparts without at-risk/high-risk conditions, and were 1.8 (95% CI, 1.4-2.3) and 3.3 (95% CI, 2.4-4.4) times higher among at-risk children in these age groups ( Table 2) .
Rates and rate ratios for IPD and pneumococcal pneumonia among children with asthma generally increased with greater severity compared with counterparts without at-risk/high-risk conditions ( Figure 1 ). Among younger children, IPD rate ratios increased from 0.9 (95% CI, .3-2.4) for those with mild disease to 6.6 (95% CI, 3.0-14.8) for those with severe disease; for pneumococcal pneumonia, corresponding rate ratios increased from 2.2 (95% CI, 1.7-3.0) to 8.8 (95% CI, 6.4-12.2). Among older children, IPD rate ratios increased from 1.7 (95% CI, .8-3.4) for those with mild disease to 2.6 (95% CI, 1.5-4.3) for those with moderate disease (insufficient data were available for those with severe disease); rate ratios for pneumococcal pneumonia increased from 1.8 (95% CI, 1.5-2.1) to 11.7 (95% CI, 8.7-15.6) for those with mild and severe disease, respectively.
Rates and rate ratios for IPD and pneumococcal pneumonia among children with at-risk conditions increased with the number of such conditions compared with counterparts without atrisk/high-risk conditions (Figure 2 ). Among younger children, IPD rate ratios increased from 1.7 (95% CI, 1.3-2.2) for those with 1 condition to 4.0 (95% CI, 1.5-10.7) for those with ≥3 conditions; for pneumococcal pneumonia, rate ratios increased from 2.1 (95% CI, 1.9-2.4) to 13.4 (95% CI, 10.4-17.2). Among older children, IPD rate ratios increased from 3.0 (95% CI, 2.1-4.1) to 32.1 (95% CI, 8.0-129.3), and rate ratios for pneumococcal pneumonia increased from 2.4 (95% CI, 2.2-2.7) to 33.1 (95% CI, 22.8-48.1). Rates and rate ratios for all-cause pneumonia were similar to those for IPD and pneumococcal pneumonia.
DISCUSSION
We identified an increased risk of IPD, pneumococcal pneumonia, and all-cause pneumonia in both high-risk children <5 years of age and those 5-17 years of age. The risk of IPD in children <5 years of age with high-risk conditions, compared with their counterparts without at-risk/high-risk conditions, varied from approximately 4-fold to approximately 26-fold across medical conditions. In high-risk children 5-17 years of age, the rate of IPD was 40-fold greater compared with their counterparts without at-risk/high-risk conditions. We also observed a greater risk for both pneumococcal pneumonia (approximately 7-fold and approximately 10-fold) and all-cause pneumonia (approximately 5-fold and approximately 8-fold) in high-risk children <5 years of age and 5-17 years of age, respectively.
We observed increased rates of IPD, pneumococcal pneumonia, and all-cause pneumonia in immunocompetent children with conditions deemed at-risk by the AAP, specifically chronic heart and lung disease, and diabetes mellitus. In addition, we identified an increased rate of disease in children with asthma, neuromuscular disorders, prematurity/low birth weight, and the combination of 2 or more of these conditions. The rate ratio for IPD among children with at least 1 at-risk condition (compared with counterparts without at-risk/high-risk conditions) was 1.8 for those <5 years of age and 3.3 for children 5-17 years of age. Although limited numbers of IPD events prevented us from reporting robust estimates of disease rates for each condition of interest, for pneumococcal pneumonia and all-cause pneumonia, consistent increases in disease rates were observed across virtually all at-risk conditions.
In children with asthma, we observed increasing pneumococcal disease rates with increasing disease severity. In children 5-17 years of age, the rates of pneumococcal pneumonia and all-cause pneumonia were >10-fold greater in children with severe asthma compared with those without at-risk/high-risk conditions. We estimated a modest 2-to 3-fold increase in all-cause and pneumococcal pneumonia among children 5-17 years of age with ≥30 days of oral steroid use and no asthma diagnosis. Comparing these rates with the >10-fold increase among children aged 5-17 years with severe asthma suggests that the use of oral steroids to treat severe asthma symptoms is not the dominant factor in the risk profile. We observed a similar pattern of increased disease in children <5 years of age with the diagnosis of severe asthma. However, we recognize that it is difficult to distinguish asthma from recurrent wheezing triggered by viral respiratory tract infection in young children, and we could not verify the accuracy of the diagnosis of severe asthma.
Rates of pneumococcal pneumonia and all-cause pneumonia in children with 2 at-risk conditions were near those of children with high-risk conditions. The incidence of pneumococcal disease in children with ≥3 at-risk conditions exceeded, in general, the incidence observed in children with high-risk conditions. The data for this study were collected during a time period when 89.3% (National Immunization Survey, 2007) of children <24 months of age had received ≥3 doses of PCV7 [10] . The Massachusetts IPD surveillance program reported that most cases of IPD in 2007 were due to serotypes 19A and 7F [11] . Similarly, Kaplan et al [12] and Pilishvili et al [13] reported a dominance of serotypes 19A and 7F in pediatric cases of IPD. The data used in this analysis do not permit serotype identification to determine if PCV13 or nonvaccine serotypes are the major cause of disease. Fortunately, as a group, overall these nonvaccine serotypes have reduced capacity to produce invasive events following colonization [14] . Ladhani et al [3] reported that children with comorbidities were more likely to suffer IPD due to the 11 serotypes found within the 23-valent pneumococcal polysaccharide vaccine (PPSV23) formulation but not in PCV13. Identifying the serotype distributions causing IPD and pneumonia in children with and without at-risk and high-risk conditions is a logical next step for development of preventive strategies in such children. In addition, understanding the mechanisms that permit increased pneumococcal disease Figure 1 . Rates of disease among children with asthma, by level of severity, compared with counterparts without at-risk/high-risk conditions. Abbreviation: CI, confidence interval.
in immunocompetent children with at-risk conditions will also be critical. Currently, for at-risk children, the specific mechanism(s) is unclear.
Although healthcare claims databases provide information on large numbers of patients with specific diagnoses who receive care for specific conditions, several limitations from the use of such databases should be noted. First, the use of operational algorithms and healthcare claims data resulted in an underestimation of the incidence of IPD (approximately 8 per 100 000 children <5 years of age) compared with national estimates from the Centers for Disease Control and Prevention (CDC) and estimates from Massachusetts (approximately 20 per 100 000) [15] . All healthcare claims databases contain errors of omission and commission in coding, which undoubtedly results in some misclassification of study outcomes. For IPD, for example, it is likely that sometimes only the ICD-9-CM diagnosis code for unspecified septicemia or bacteremia is recorded on the healthcare claim form, without an accompanying diagnosis code for pneumococcus. Thus, whereas such encounters would be correctly identified as invasive disease, they would not be correctly identified as IPD. In addition, private healthcare claims databases-such as the ones used in this study-include information for commercially insured populations, which often have an overall lower risk of disease. We note, however, that the Figure 2 . Rates of disease among children with at-risk conditions, by number of conditions, compared with counterparts without at-risk/high-risk conditions. Abbreviation: CI, confidence interval.
age distribution of IPD cases in our study is similar to the distribution that has been reported by the CDC. Because the study databases were de-identified prior to their release to study investigators, it was not possible to formally evaluate our case-ascertainment algorithms using medical record review, and thus data validation was not performed.
Second, use of operational algorithms and available diagnostic, procedure, and drug evidence undoubtedly resulted in misclassification of risk profiles; it was not possible, however-as noted above-to formally evaluate the accuracy of these algorithms. We did evaluate the sensitivity of our study results when employing alternative approaches to characterizing risk profiles, and found our conclusions to be largely unchanged (Supplementary Table 4 ). Third, classification of asthma disease severity was based on asthma-related drug use and hospitalization rather than disease-specific functional data. In addition, among those <5 years of age, children diagnosed with asthma may actually have had recurrent wheezing of another etiology (ie, viral respiratory infection). Despite these limitations, we observed a distinct increase in pneumococcal disease risk across our 3 stratifications of asthma. Fourth, young children may be more likely to have a diagnosis of prematurity recorded compared with children ≥5 years of age, whose diagnosis may be sufficiently remote not to be included in the coding, therefore limiting its value as a comorbid condition in older age groups.
Fifth, all-cause pneumonia was identified using ICD-9-CM diagnostic codes (which do not require radiographic or any other confirmation), and includes cases without any radiographic confirmation, as well as those with radiographic infiltrates of noninfectious origin. Although children with asthma (and perhaps other chronic lung diseases) may be more likely to be overdiagnosed with pneumonia than other children, we note that when excluding children with evidence of asthma from the at-risk group, rate ratios were largely unchanged. Finally, children with public or no health insurance are not represented in the study databases. We note that some of the above-described limitations may be avoided by using alternative, more clinically rich databases-such as those comprising administrative, clinical, and claims information developed through the HMO Research Network Virtual Data Warehousethat could be used to define more accurate operational and case-ascertainment algorithms, validate the algorithms, and audit study findings.
These data demonstrate that despite widespread use of PCV7 and an overall decline in rates of IPD, all-cause pneumonia, and pneumococcal pneumonia in children [11, 16] , disease rates remain disproportionately high in children with high-risk and atrisk conditions. As vaccine failure is an unlikely explanation for the increased risk of disease in high-risk and at-risk children [17] , a more likely reason is increased risk of disease due to serotypes not covered in PCV7. We have identified a group of children who are at increased risk for pneumococcal disease due to having medical conditions not currently included within the ACIP and AAP recommendations for prevention. These include children with asthma, especially those with moderate and severe disease as we have defined them, as well as children with asthma and concurrent morbidities such as lung or heart disease, diabetes, or neuromuscular disorders.
The replacement of PCV7 with PCV13 in 2010 for all children <71 months of age with selected chronic medical conditions, and the expansion in recommendations for use of PCV13 to naive children 6-18 years of age with HIV or asplenia, is likely to further decrease the incidence-but not necessarily the elevated risk-in children with chronic medical conditions. Increased compliance with recommendations for use of PPSV23 in children with chronic medical conditions could potentially reduce the excess risk; however, effectivenessespecially against pneumococcal pneumonia in this populationhas been inadequately studied. Further research is needed to confirm our findings in the post-PCV13 era and to better understand the efficacy of PPSV23 in this population. If our findings of persistent elevated risk in children with at-risk conditions are confirmed in the PCV13 era, further understanding of why these children are at increased risk will be necessary.
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